Aquestive Therapeutics Leadership

Daniel Barber joined Aquestive in July 2007. Prior to joining Aquestive, Mr. Barber held various positions with Quest Diagnostics in their corporate planning and international divisions. Over the last ten years Mr. Barber has been instrumental in the growth of Aquestive Therapeutics. In 2010, Mr. Barber had executive oversight of the company’s launch activities for Aquestive’s first two FDA approved products. In 2013, Mr. Barber helped lead the company’s effort to develop an internal pipeline of proprietary assets. Since that time he has had executive responsibility for Aquestive’s pipeline and partnership activities. Mr. Barber received his BA degree from State University of New York at Geneseo and an MBA from Seton Hall University.

Mark Schobel was appointed as Chief Innovation & Technology Officer of Aquestive in 2014 after serving as the Company’s Chief Executive Officer, Co-President and a member of its Board of Directors since November 2005. From March 2001 to November 2005, he was the Global Head of New Technology and Product Innovation for the Consumer Health Business Unit at Novartis where he pioneered thin film delivery of systemic drugs. Prior to Novartis, Mr. Schobel held various general management positions with Reed & Carnrick Pharmaceuticals, Warner-Lambert, and Pharmaceutical Formulations Inc.

Gary Slatko is a Chief Medical Officer at AQUESTIVE THERAPEUTICS, INC. and is based in Warren, New Jersey. He has worked as Vice President, Care Management at GSK; Director, New Product Planning (Manager, Clinical Programs) - DuPont-Merck at DuPont; and Vice President, Medical Services at Astra Zeneca. Gary attended West Chester University between 1990 and 1992, University of Pittsburgh School of Medicine between 1982 and 1985, and University of Miami Miller School of Medicine between 1978 and 1982.

Track record of leading teams, positioning companies for high growth, to raise capital or for a strategic transaction. International scope includes operations in Asia, Europe and North America.

• Proven financial, operations, transaction, and commercial experience working with private equity, venture capital and HNW investors. Experience in highly leveraged environments.



•Transformational C-suite executive and strategic business partner working closely with Chief Executive Officers and other senior executives to operate all aspects of fast-paced entrepreneurial businesses and global, high growth environments.

Successful exits:

• As Global CFO, counseled founder/1st time CEO on sale in 2015 of Synowledge LLC to Bioclinica, a portfolio company of JLL/Waterstreet Healthcare Partners for 10x multiple.

• Prepared ArisGlobal (SaaS company) for capital transaction.

• As CFO, positioned JHP Pharmaceuticals LLC for sale by Morgan Stanley Private Investments to Warburg Pincus (2012) and ultimately to Par Pharmaceuticals (2014) for 12x multiple.

• Consultant and Board Member at Eaux Vives Water (Eska) on sale in May, 2017 to strategic partner.

Contact: ernietoth@bellairadvisors.com.

•CFO that is process excellent, financially disciplined and focused

•Strong financial reporting background (including SEC) that is timely, accurate, and insightful

•Provide pro-active business intelligence to the executive team

•Promote team alignment of strategic mission, goals and operations

•Operational orientation that can dig into a business, root out costs, and work to improve efficiency

•Partner with CEO on road shows and investor presentations raising debt and capital

•Manage capital budgeting and financial planning process

•Working capital management and financial modeling

•Collaborate on business development activities including new product launches & acquisitions

•Highly leveraged environments

Ken Marshall joined Aquestive in 2017. Prior to that Mr. Marshall served as US President and Global Chief Marketing Officer for Aerocrine Inc. In that role he developed the global marketing strategy and led all aspects of the US business. Between 2008 and 2011, Mr. Marshall served as Vice President of Sales and Marketing for Ikaria, a drug/device company focused in critical care. Mr. Marshall also spent 17 years with GlaxoSmithKline and held several senior positions including Vice President of Marketing for the Neurology, Urology, Lifecycle and HIV business units. Mr. Marshall received his BS/BA in Marketing and Economics from Western Carolina University and M.B.A from Houston Baptist University.

Daniel Barber joined Aquestive in July 2007. Prior to joining Aquestive, Mr. Barber held various positions with Quest Diagnostics in their corporate planning and international divisions. Over the last ten years Mr. Barber has been instrumental in the growth of Aquestive Therapeutics. In 2010, Mr. Barber had executive oversight of the company’s launch activities for Aquestive’s first two FDA approved products. In 2013, Mr. Barber helped lead the company’s effort to develop an internal pipeline of proprietary assets. Since that time he has had executive responsibility for Aquestive’s pipeline and partnership activities. Mr. Barber received his BA degree from State University of New York at Geneseo and an MBA from Seton Hall University.